Results 171 to 180 of about 284,309 (242)

Targeting neutrophil extracellular traps in metabolic and immune niche: Nanomaterials for diabetes tissue regeneration

BMEMat, EarlyView.
The effects of NETs on regeneration of various diabetic tissues, and strategies targeting NETs for diabetes tissue regeneration. In the diabetic environment, NETs undergo complex metabolic and immune reprogramming, leading to dynamic changes in antibacterial and proinflammatory functions, and affecting regeneration of multiple systemic tissues.
Xinyi Jiang, Muxin Yue, Kai Mao, Boon Chin Heng, Noor Azlin Yahya, Yunsong Liu, Zheng Li   +6 more
wiley   +1 more source

Prevention of Subsequent L-Asparaginase Hypersensitivity in Children Through Premedication: A Single-Center Experience. [PDF]

J Pediatr Pharmacol Ther
Saligupta P, Choed-Amphai C, Sathitsamitphong L, Lao-Araya M.   +3 more
europepmc   +1 more source

A Novel Patient‐Specific Landmark‐Guided Approach for Intramuscular Botulinum Neurotoxin Injections Into the Rotator Cuff: A Cadaveric Study

Clinical Anatomy, EarlyView.
ABSTRACT Myofascial pain syndrome (MFPS) causes chronic shoulder pain. Supraspinatus and infraspinatus, rotator cuff muscles innervated by the suprascapular nerve, are commonly affected. Intramuscular botulinum neurotoxin (BoNT) injections near motor points (i.e., visible nerve branch entry sites used as a proxy for motor endplates) are an effective ...
Dave Osinachukwu Duru, David Kwan Ryung Lee, Gavin E. Jarvis, Niel Kang, Salma Chaudhury, Cecilia Brassett   +5 more
wiley   +1 more source

Intraosseous sarcoidosis imitating peri‐implantitis: A case study

Clinical Advances in Periodontics, EarlyView.
Abstract Background Sarcoidosis is a multisystem granulomatous disorder of unknown cause, typically affecting the lungs and lymph nodes, but it can also involve the eyes, skin, heart, bones, and other organs. The exact cause is unclear, but genetic factors and environmental triggers like infections, chemicals, or dust may play a role.
Magdalena Orlowska, David S. Gottlieb, Kenneth S. Kornman   +2 more
wiley   +1 more source

Voclosporin‐induced gingival enlargement: A case report

Clinical Advances in Periodontics, EarlyView.
Abstract Background Drug‐influenced gingival enlargement (DIGE) is a recognized adverse effect of certain medications, particularly immunosuppressants like cyclosporin and tacrolimus. However, there have been no documented cases of DIGE associated with voclosporin, a newer calcineurin inhibitor used primarily to treat lupus nephritis.
Francesca Racca, Jessica M. Greco, Dimitris N. Tatakis   +2 more
wiley   +1 more source

Corticosteroids as adjunctive therapy in patients with acute/subacute paracoccidioidomycosis presenting a severe paradoxical inflammatory reaction: Two case reports and literature review. [PDF]

Braz J Infect Dis
Stringelli-Brandão P, Fuga MP, Sguassábia MK, Rocha IH, Silva-Vergara ML.   +4 more
europepmc   +1 more source

Engineering Lipid Nanoparticles for Precision RNA Delivery: Design Principles, Targeting Strategies, and Clinical Prospects

Cancer Nexus, EarlyView.
ABSTRACT Lipid nanoparticles (LNPs) represent the most clinically advanced platform for RNA delivery and have enabled major breakthroughs in vaccines and gene therapies. However, their broader application is still limited by inefficient extrahepatic delivery, immunogenicity, and insufficient control over tissue‐ and cell‐specific targeting. This review
Yu Han, Ying Wang, Xintao Gao, Yan Lei, Yantao Li, Zhiyong Tang   +5 more
wiley   +1 more source

Steroid-sparing strategies for managing immune-related adverse events. [PDF]

J Immunother Cancer
Huang JJ, YousefiAsl M, Singh N, Grivas P, Bhatia S.   +4 more
europepmc   +1 more source

Serious Infection in Crohn's Disease Patients Treated With Ustekinumab: US Food and Drug Administration Active Postmarket Risk Identification and Analysis in the Sentinel Initiative

Clinical Pharmacology &Therapeutics, EarlyView.
The U.S. Food and Drug Administration (FDA) used an Active Postmarket Risk Identification and Analysis (ARIA) system to address a safety issue (serious infection) identified during clinical review of an application to market ustekinumab as a treatment for Crohn's disease (CD). FDA used an active‐comparator new‐user cohort design, data from six Sentinel
Joel L. Weissfeld, Geetha S. Iyer, Suna C. Seo, Andrew Giffin, Andrew L. Simon, Sheryl A. Kluberg, Emma R. Hoffman, Jamal T. Jones, Sarah K. Dutcher, Joyce A. Korvick   +9 more
wiley   +1 more source

Managing Acute Severe Ulcerative Colitis in 2025 and Beyond. [PDF]

Curr Gastroenterol Rep
Goyal MK, Hassan SA, Berinstein JA.
europepmc   +1 more source